MTA-cooperative PRMT5 inhibitors are designed to selectively target the PRMT5 form in MTAP-deficient cancer cells by enhancing the natural inhibitory effect of accumulated MTA, sparing normal tissues. This evidence concerns the gene MTAP and cancer.